Bidirectional Cohort Study of a Prognosis Model for Acute-on-chronic Liver Failure

April 21, 2026 updated by: The Second Affiliated Hospital of Chongqing Medical University

Bidirectional Cohort Study on Prognostic Model Construction for Acute-on-Chronic Liver Failure

This study constitutes a bidirectional cohort investigation. By collating laboratory parameters and clinical data-including plasma and peripheral blood mononuclear cell (PBMC) analyses-from patients with acute-on-chronic liver failure, it aims to provide a reference framework for predicting prognosis and the occurrence of complications.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Chongqing, China
        • Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Hospitalized patients diagnosed with Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) .

Description

Inclusion Criteria:

•Clinical diagnosis of Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF)

Exclusion Criteria:

  • age < 18 years
  • extrahepatic organ failure unrelated to ACLF
  • active malignancy
  • co-infection with other hepatitis viruses or human immunodeficiency virus (HIV)
  • prior liver transplantation
  • use of immunosuppressants within 6 months before enrollment
  • unclear history of antiviral therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Primary endpoint was all-cause mortality at days 28, 90, 180, and 360.
Time Frame: Days 28, 90, 180, and 360
Days 28, 90, 180, and 360

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Second Affiliated Hospital of Chongqing Medical University

Investigators

  • Study Director: Shan Zhong, professor, Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

December 18, 2025

First Submitted That Met QC Criteria

April 21, 2026

First Posted (Actual)

April 23, 2026

Study Record Updates

Last Update Posted (Actual)

April 23, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025IIT599

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe